India and Uzbekistan Establish Pharmaceutical and Nutraceutical Trade Corridor to Expand Eurasian Market Access

In a strategic development set to reshape cross-border healthcare trade between South Asia and Eurasia, the Ministry of Health of the Republic of Uzbekistan has aligned with Nutrify Today and Pharma Eurasia to formalise a structured Indo-CIS pharmaceutical and nutraceutical corridor, positioning Uzbekistan as the region’s premier gateway to the Commonwealth of Independent States (CIS) and the wider Eurasian market.

The trilateral initiative integrates policy facilitation, global industry leadership, and a dedicated commercial exhibition platform, creating a scalable and compliance-driven trade architecture for Indian and global manufacturers seeking structured access into high-growth Eurasian markets.

Why This Matters: A USD 10 Billion Growth Opportunity

The CIS dietary supplements market currently exceeds USD 5.8 billion annually, with the broader CIS + Eurasia nutraceutical opportunity estimated at USD 7-10 billion, and growing rapidly, driven by:

• Rising adoption of preventive healthcare and condition-specific supplementation
• Expansion of organised pharmacy and retail chains across Russia, Central Asia, and the Caucasus
• Strengthening regulatory frameworks that favour compliant, quality-certified products
• A growing middle class demanding vitamins, botanicals, and functional nutrition

For Indian pharmaceutical and nutraceutical exporters, this corridor represents one of the most structured and policy-backed market-entry opportunities available today.

Uzbekistan as the Eurasian Pharma-Nutra Gateway

Uzbekistan has rapidly transformed into a regional pharmaceutical and nutraceutical hub through targeted industrial policy, including:

• Dedicated Pharma Parks and industrial clusters designed to attract FDI and contract manufacturing
• Regulatory modernisation aligned with international compliance standards
• Strategic geographic positioning between India, Russia, and Central Asia
• Trade-focused institutional reforms and investment facilitation frameworks

Tashkent’s Pharma Park now offers foreign pharmaceutical and nutraceutical companies a structured pathway to establish a regional manufacturing or distribution presence, with government-backed institutional support.

The Dual-City Architecture: Mumbai + Tashkent

The corridor operates on a synchronised dual-market model:

• Mumbai (Sumflex & C-Suite Summit): Global leadership, investment dialogue, and strategic policy convergence, convening CEOs, regulators, investors, and policy leaders from across the pharmaceutical and nutraceutical value chain.
• Tashkent (Pharma Eurasia 2026): Trade execution, regulatory collaboration, and CIS market integration, where corridor discussions transition into tangible trade agreements, partnerships, and regulatory pathways.

This structure connects diplomacy, compliance intelligence, and commercial access across two of the world’s most strategically positioned cities for the health industry.

Pharma Eurasia 2026: The Commercial Execution Platform

The commercial activation of this corridor will take place at Pharma Eurasia 2026, scheduled for 20–22 May 2026 in Tashkent, Uzbekistan. The platform convenes:

• Pharmaceutical and nutraceutical manufacturers
• Ingredient and excipient suppliers
• Contract manufacturers and CDMOs
• Regulatory authorities and compliance solution providers
• Distributors and trade buyers across CIS and Eurasia

Under the new alignment, Pharma Eurasia becomes the annual institutional marketplace for the Indo-CIS health trade corridor, providing direct buyer access, government-backed engagement, and structured market-entry facilitation.

Structured Indo–CIS Corridor: Key Focus Areas

• Regulatory harmonisation and structured bilateral policy dialogue
• Supply chain digitisation and documentation standardisation
• Bilateral investment facilitation and joint venture frameworks
• Clinical research and R&D collaboration
• Institutional trade matchmaking and market commercialisation enablement

Nutrify Today will deploy AI-driven regulatory intelligence and compliance infrastructure to support transparent and scalable cross-border nutraceutical trade.

Leadership Perspectives

“Uzbekistan is poised to emerge as a strategic bridge between India and the CIS in pharmaceuticals and nutraceuticals. Through this collaboration, we are institutionalising a transparent, technology-enabled trade ecosystem that creates lasting value for all stakeholders.”

— Abdulla Azizov, First Deputy Minister of Health & Chairman, Pharmaceutical Industry Development Agency, Republic of Uzbekistan

“With Sumflex anchoring global leadership in Mumbai and Pharma Eurasia providing the structured commercial platform in Tashkent, this initiative transforms vision into executable trade architecture.”

— Khasim, MTI Executive Director, Nutrify Today

“Pharma Eurasia is a structured bridge between global pharmaceutical leadership and high-growth Eurasian markets. Our objective is a long-term, policy-aligned ecosystem where innovation, compliance, and cross-border trade converge in a sustainable and scalable manner.”

— M. Harikrishnan, Vice President, Tricornio Technologies & Project Director, Pharma Eurasia

“Uzbekistan is well-positioned to serve as a regional conduit between India and CIS markets. Our engagement with Nutrify Today and Pharma Eurasia embeds transparency and digital tools into a more institutionalised trade and collaboration architecture, while actively welcoming joint-venture cooperation in manufacturing, technology transfer, and regional expansion.”

— Kamila Mirzaeva, Chief International Relations Specialist, Ministry of Health, Republic of Uzbekistan

Strategic Alignment at a Glance

Global Call for Participation

Pharmaceutical and nutraceutical manufacturers, ingredient innovators, regulatory solution providers, and contract manufacturers from India, the United States, Southeast Asia, and Europe are invited to exhibit at Pharma Eurasia 2026.